Diabetes, Hypogonadism
Conditions
Brief summary
The purpose of this study is to test the effect of testosterone treatment on glycaemic control, arterial stiffness and IMT in hypogonadal men with type 2 diabetes treated with insulin.
Detailed description
There is epidemiological data linking low serum testosterone levels in men with the development of diabetes. Clinical trials have indicated a potential benefit of testosterone treatment in improving diabetic control and insulin resistance. Type 2 diabetes is also associated with changes in arterial stiffness and IMT which are known to be linked to the presence of cardiovascular disease. Artificially induced hypogonadism results in increasing arterial stiffness whilst testosterone is known to improve risk factors for vascular disease and act as a vasodilator. The purpose of this pilot study is to test the effect of six months of testosterone replacement, given as testosterone esters 200mg from Sustanon 250 IM injection, on diabetes control in hypogonadal men with type 2 diabetes treated with insulin.
Interventions
DRUGTestosterone
Sustanon- 200mg intramuscular testosterone
DRUG0.9% saline
Saline intramuscular injection every two weeks
Sponsors
Barnsley Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
MALE
Age
40 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* males over 40 years old * type 2 diabetes treated with insulin * serum testosterone less than 12nmol/L on 2 consecutive morning samples * symptoms attributable to hypogonadism
Exclusion criteria
* current or previous breast cancer * current or previous prostate cancer * raised prostate specific antigen or abdominal digital rectal examination suspicious of prostate cancer unless diagnosis excluded after specialist urology opinion and/or prostate biopsy * severe symptoms of benign prostatic hypertrophy * treatment with testosterone in the three months prior to the trial * investigational drug treatment in the three months prior to the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The effect of 6 months of testosterone replacement on diabetes control measured by HbA1c in hypogonadal men with type 2 diabetes treated with insulin. | 6 months |
Secondary
| Measure | Time frame |
|---|---|
| The effect of testosterone on ultrasound measured intima-media thickness of the common carotid artery in the study population | 6 months |
| The effect of testosterone on male hypogonadism as assessed by the Ageing Males Symptoms (AMS) | 6 months |
| The effect of testosterone on markers of vascular risk; blood pressure, serum lipid levels, weight, waist circumference, body fat percentage, | 6 months |
| urinary micro-albumin, tumour necrosis factor alpha, and highly sensitive C reactive protein levels in the study population. | 6 months |
| The effect of the CAG repeat polymorphism in exon 1 of the androgen receptor gene on the response of the study population to testosterone. | 6 months |
Countries
United Kingdom
Outcome results
None listed